NewsRoom Articles - Page 45 of 154 - PsychedelicNewsWire (PNW)

WednesdayNov 02, 2022 1:33 pm

Research Finds That Psychedelics Users Are More Connected to Nature

We are currently in the midst of a major psychedelics renaissance. Decades after the United States outlawed the production, purchase and consumption of psychedelic drugs such as LSD and MDMA, states are loosening their psychedelic policies and allowing for more research into these mind-altering drugs. Furthermore, a growing number of people are using psychedelics for recreational and medical purposes, with a recent study finding that around 28% of Americans have used LSD, MDMA, ketamine, DMT, mescaline, salvia or psilocybin. A new study has now found that individuals who consume hallucinogenic drugs such as psilocybin tend to be more connected to…

TuesdayNov 01, 2022 12:19 pm

US DEA Facing Fresh Lawsuits After Denying Psilocybin Waiver, Rescheduling Request

For more than a year, a palliative care specialist has been fighting to be granted permission by the U.S. Drug Enforcement Administration (DEA) to administer psilocybin to his patients. Dr. Sunil Aggarwal had requested a federal waiver under the Right to Try statute, which would have allowed him to administer the psychedelic to his patients with terminal illnesses. Aggarwal explained that Right to Try laws clearly stipulate that severely ill individuals qualified for investigational drugs, including psychedelics. However, the DEA rejected the request as well as a petition the doctor filed to reschedule psilocybin. In its argument, the federal agency…

MondayOct 31, 2022 12:05 pm

Compass Pathways Announces First-Ever Phase 3 Human Psilocybin Trial

Psychedelics have long been heralded for their numerous benefits, with recent studies showing that these substances may be useful in the treatment of various mental health conditions. These benefits have increased interest in these substances, with Compass Pathways PLC (NASDAQ: CMPS) recently announcing that the company plans to begin a phase 3 human trial, which will investigate the effectiveness psilocybin in treating depression this year. This will be the first human trial of this magnitude involving psychedelic therapy globally. Compass Pathways is a mental healthcare company focused on transforming patient experiences in mental healthcare. The company has developed a psilocybin…

FridayOct 28, 2022 10:18 am

Microscopy Provides Insights on Psychedelics Action Inside Neuropathways

Psychedelics have been used for centuries by different cultures, with their popularity in the 1960s prompting research into their benefits. Until now, however, researchers are yet to fully understand how these substances actually work in the brain. Associate professor Alex Kwan of the Meinig School of Biomedical Engineering is mapping the neural response of these hallucinogens in the brain through the use of optical microscopy. This may, in the future, lead to the development of treatments for cluster headaches and substance-use disorders as well as fast-acting antidepressants. Kwan stated that while researchers knew how psychedelics worked at the structural level,…

ThursdayOct 27, 2022 12:30 pm

Venture Studio Establishes Equity Crowdfunding Drive to Boost Psychedelics Therapies

Nucleus will soon launch a crowdfunding campaign whose goal is to expand the interactions individuals have with the psychedelics industry. The objective of the psychedelics venture studio, which operates as an Iter Investments subsidiary, is to drive psychedelic-assisted therapy forward in the middle of the current global mental health crisis. Iter Investments’ active portfolio is comprised of more than 15 companies with special access to new investments, including clinics such as Wesana Health and Awakn Life Sciences; active psychedelic ingredient suppliers, including Psygen; drug research and development companies such as Beckley Psytech, Psilera, Clairvoyant, Apex Labs, Reset Pharma, Wesana, Freedom…

WednesdayOct 26, 2022 3:09 pm

As Competition Stiffens, Patent Wars Intensify in Psychedelics Space

The medicinal psychedelics space is continuing to grow as interest from the public increases and more research on these substances is conducted. Additionally, issued psychedelic patents portfolios are getting larger, with challenges to these patents being filed with the U.S. Patent and Trademark Office. These patents may shape the trajectory of this burgeoning space, especially in the short term. The need for psychedelic compounds to be treated as common pharmaceutical medications is one of the primary reasons why some patents in this infant industry have been challenged. In the past, patents helped encourage innovation in biopharmaceutical companies by protecting the…

TuesdayOct 25, 2022 12:39 pm

Survey Finds No Link Between Psychedelics Use, Cancer Risk

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened risk of developing cancer. The research in question was conducted in 1967, with those involved reporting that the use of LSD caused chromosomal damage in white blood cells. Subsequent studies also suggested that exposure to LSD could have carcinogenic potential. For their study, the researchers focused on expanding on a 2021 study that explored the…

MondayOct 24, 2022 12:04 pm

What You Should Know About Colorado’s Psychedelics Ballot Measure

Psychedelic drugs, which can change an individual’s perception and induce hallucinations, are classified under Schedule I of the Controlled Substances Act. Drugs under this schedule are said to have no legitimate medical use and a high potential for abuse. However, numerous studies have shown that psychedelics such as psilocybin mushrooms could actually be useful in the treatment of various mental conditions, including anxiety, depression and post-traumatic stress disorder. Now, the state of Colorado may become the second in the country to permit the use of various psychedelics, which are still prohibited under federal law. The first state in the country…

MondayOct 24, 2022 10:30 am

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New Drug (“IND”) package for SP-26, intends to pursue 505(b)(2) regulatory pathway Ketamine was approved in the United States in 1970 and has been used extensively for surgical anesthesia. Since then, use of the drug in small doses has expanded considerably to treat pain and treatment-resistant…

FridayOct 21, 2022 2:47 pm

DEA Significantly Increases 2023 Production Quotas for Cannabis, Psychedelics

The U.S. Drug Enforcement Administration (DEA) has proposed a significant increase to the cannabis and psychedelics quota to be produced legally for research in 2023. In a new notice, the federal agency proposed that the new quota for marijuana be increased to 6.7 million grams. This is twice as much as its quota for 2022, which was 3.2 million grams, and more than three times its 2021 quota, which stood at 2 million grams. Increasing the marijuana quota will be easy, especially since the federal agency authorized additional marijuana manufacturers earlier this year. These approved producers can now apply for…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000